News Johnson & Johnson Borsa Italiana

Equities

4JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 08:44:23 04/06/2024 pm IST			5-day change	1st Jan Change
135.1 ^EUR	-0.15%		-0.54%	-3.78%

05:10pm	J&J: promising trial for Tecvayli in multiple myeloma	CF
12:40pm	Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

J&J: promising trial for Tecvayli in multiple myeloma	08:40pm	CF
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	08:08pm	PU
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	04:10pm	MT
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	03:10pm	AQ
J&J must pay $260 million in latest talc trial, Oregon jury says	06:06am	RE
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	04/06	MT
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	04/06	CI
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	04/06	CI
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	04/06	CI
Johnson & Johnson Completes Acquisition of Shockwave Medical	03/06	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	03/06	AQ
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	03/06	CI
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	03/06	RE
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	03/06	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06	RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06	RE
Johnson & Johnson Announces First Data from the Phase 3 PALOMA-3 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib	01/06	CI
Sector Update: Health Care Stocks Higher Late Afternoon	01/06	MT
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06	RE
Sector Update: Health Care Stocks Advance Friday Afternoon	31/05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST